LipoScience has landed a major partner, Laboratory Corporation of America, for the promotion and sale of its disease designed to detect heart disease.

LabCorp, which is based in the Triad, will make LipoScience’s LipoProfile test available to some 220,000 physicians as well as hospitals, healthcare providers and other customers.

Terms of the deal were not disclosed.

“This multi-year agreement will make the LipoProfile test readily available through LabCorp’s sales and distribution network and will add an important cardiovascular test to LabCorp’s comprehensive menu of testing services,” LipoScience said in a statement.

According to LipoScience, its test has been shown to be “superior” to measuring of cholesterol in predicting coronary disease problems.

“Entering into this agreement with LabCorp accelerates our strategy of making our technology available for broad use in clinical laboratories worldwide,” said Richard Brajer, LipoScience’s chief executive officer. “Clinicians increasingly understand the need to go beyond cholesterol measurement in assessing risk for heart disease and monitoring response to therapy. This relationship with LabCorp will help address that

The test has been used since 1999.